Drug Trial Radar · NCT07249463
Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Dec 8, 2025
Primary completion
Mar 23, 2027
Study completion Mar 23, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study has the purpose to demonstrate prospect of benefit of EDI048 on clinical signs and symptoms of cryptosporidiosis to facilitate trial in target population, pediatric patients. This study aims to investigate the efficacy of a new chemical entity, EDI048, in a controlled human infection model of cryptosporidiosis induced by administration of ABO809 in healthy adults, who become symptomatic with disease thereby demonstrating a prospect of benefit for use of EDI048 in children afflicted with cryptosporidiosis.
Conditions
- Cryptosporidiosis
Interventions
Cryptosporidium parvum oocysts (ABO809)Biological
ABO809 oral suspension, single dose
EDI048Drug
EDI048 administered orally
PlaceboOther
Placebo administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Average stool grade after the initiation of EDI048 or placebo treatmentTime frame: Day 3, Day 4 and Day 5
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Pharmaron Inc
Baltimore, Maryland · Recruiting
Cinn Children Hosp Medical Center
Cincinnati, Ohio · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.